Literature DB >> 22726075

WFH: closing the global gap--achieving optimal care.

Mark W Skinner1.   

Abstract

For 50 years, the World Federation of Hemophilia (WFH) has been working globally to close the gap in care and to achieve Treatment for All patients, men and women, with haemophilia and other inherited bleeding disorders, regardless of where they might live. The WFH estimates that more than one in 1000 men and women has a bleeding disorder equating to 6,900,000 worldwide. To close the gap in care between developed and developing nations a continued focus on the successful strategies deployed heretofore will be required. However, in response to the rapid advances in treatment and emerging therapeutic advances on the horizon it will also require fresh approaches and renewed strategic thinking. It is difficult to predict what each therapeutic advance on the horizon will mean for the future, but there is no doubt that we are in a golden age of research and development, which has the prospect of revolutionizing treatment once again. An improved understanding of "optimal" treatment is fundamental to the continued evolution of global care. The challenges of answering government and payer demands for evidence-based medicine, and cost justification for the introduction and enhancement of treatment, are ever-present and growing. To sustain and improve care it is critical to build the body of outcome data for individual patients, within haemophilia treatment centers (HTCs), nationally, regionally and globally. Emerging therapeutic advances (longer half-life therapies and gene transfer) should not be justified or brought to market based only on the notion that they will be economically more affordable, although that may be the case, but rather more importantly that they will be therapeutically more advantageous. Improvements in treatment adherence, reductions in bleeding frequency (including microhemorrhages), better management of trough levels, and improved health outcomes (including quality of life) should be the foremost considerations. As part of a new WFH strategic plan (2012-2014) the WFH has identified several key initiatives for particular emphasis - continuation of the Global Alliance for Progress (GAP) program, a new initiative to address underserved countries and regions (The Cornerstone Initiative), enhancing health outcomes research and analysis, and a new research mentorship program. Despite our progress to date in closing the global gap in care, our work is not complete. Too many patients remain undiagnosed and too few receive adequate treatment. This paper will also discuss historical, present and future challenges and opportunities to close the gap in care and achieve Treatment for All.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22726075     DOI: 10.1111/j.1365-2516.2012.02822.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  25 in total

Review 1.  Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?

Authors:  Vincenzo De Angelis; Antonio Breda
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years.

Authors:  Raimondo De Cristofaro; Massimo Franchini
Journal:  Blood Transfus       Date:  2019-04-30       Impact factor: 3.443

3.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

Review 4.  Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future.

Authors:  Victor Jiménez-Yuste; Günter Auerswald; Gary Benson; Thierry Lambert; Massimo Morfini; Eduardo Remor; Silva Zupančić Salek
Journal:  Blood Transfus       Date:  2014-07       Impact factor: 3.443

5.  Evolution of Hemophilia Care in India.

Authors:  Kanjaksha Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2018-12-19       Impact factor: 0.900

Review 6.  Women and bleeding disorders: diagnostic challenges.

Authors:  Paula D James
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B.

Authors:  J Michael Soucie; Paul E Monahan; Roshni Kulkarni; Barbara A Konkle; Marshall A Mazepa
Journal:  Blood Adv       Date:  2018-08-28

8.  Management of Haemophilia in Developing Countries: Challenges and Options.

Authors:  Kanjaksha Ghosh; Kinjalka Ghosh
Journal:  Indian J Hematol Blood Transfus       Date:  2015-06-18       Impact factor: 0.900

Review 9.  Haemophilia.

Authors:  Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette
Journal:  Nat Rev Dis Primers       Date:  2021-06-24       Impact factor: 52.329

Review 10.  Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.

Authors:  Pratima Chowdary
Journal:  Int J Hematol       Date:  2018-10-09       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.